Merck Begin Period Cash Flow vs Cash Per Share Analysis

MRK Stock

USD 101.24 1.38 1.38%

Merck financial indicator trend analysis is infinitely more than just investigating Merck Company recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Merck Company is a good investment. Please check the relationship between Merck Begin Period Cash Flow and its Cash Per Share accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Merck Company. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

Begin Period Cash Flow vs Cash Per Share

Begin Period Cash Flow vs Cash Per Share Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Merck Company Begin Period Cash Flow account and Cash Per Share. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Merck's Begin Period Cash Flow and Cash Per Share is 0.54. Overlapping area represents the amount of variation of Begin Period Cash Flow that can explain the historical movement of Cash Per Share in the same time period over historical financial statements of Merck Company, assuming nothing else is changed. The correlation between historical values of Merck's Begin Period Cash Flow and Cash Per Share is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Begin Period Cash Flow of Merck Company are associated (or correlated) with its Cash Per Share. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cash Per Share has no effect on the direction of Begin Period Cash Flow i.e., Merck's Begin Period Cash Flow and Cash Per Share go up and down completely randomly.

Correlation Coefficient

0.54

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Cash Per Share

Most indicators from Merck's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Merck Company current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Merck Company. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

At this time, Merck's Selling General Administrative is quite stable compared to the past year. Sales General And Administrative To Revenue is expected to rise to 0.18 this year, although the value of Tax Provision will most likely fall to about 2.2 B.

	2021	2022	2023	2024 (projected)
Gross Profit	35.1B	41.9B	44.0B	46.2B
Total Revenue	48.7B	59.3B	60.1B	32.4B

Gross Profit Total Revenue

Merck fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Accounts Payable	Property Plant And Equipment Gross	Common Stock Total Equity	Short Term Investments
Total Assets		0.57	0.66	0.79	0.87	0.53	0.28	0.88	0.73	1.0	0.23	0.74	0.57	0.3	0.74	0.93	0.62	0.15	0.7	0.98	0.3	0.8	0.5	0.27	0.95	0.16
Short Long Term Debt Total	0.57		0.95	0.75	0.25	0.89	0.91	0.75	0.2	0.59	0.69	0.11	0.88	-0.27	0.95	0.58	0.95	-0.55	0.97	0.5	0.27	0.24	0.77	0.75	0.64	-0.24
Other Current Liab	0.66	0.95		0.77	0.39	0.87	0.84	0.82	0.27	0.68	0.55	0.26	0.89	-0.14	0.96	0.66	0.92	-0.44	0.98	0.61	0.22	0.37	0.73	0.69	0.74	-0.09
Total Current Liabilities	0.79	0.75	0.77		0.4	0.61	0.6	0.93	0.42	0.81	0.64	0.28	0.57	-0.25	0.77	0.86	0.76	-0.43	0.82	0.73	0.53	0.37	0.86	0.4	0.87	-0.17
Total Stockholder Equity	0.87	0.25	0.39	0.4		0.33	-0.07	0.59	0.79	0.84	-0.16	0.9	0.4	0.67	0.47	0.72	0.35	0.57	0.4	0.9	0.07	0.93	0.06	0.1	0.72	0.37
Property Plant And Equipment Net	0.53	0.89	0.87	0.61	0.33		0.74	0.65	0.33	0.53	0.71	0.12	0.97	-0.14	0.84	0.57	0.9	-0.36	0.87	0.5	0.16	0.39	0.63	0.89	0.53	-0.4
Net Debt	0.28	0.91	0.84	0.6	-0.07	0.74		0.57	-0.21	0.33	0.66	-0.23	0.74	-0.51	0.8	0.28	0.84	-0.73	0.83	0.18	0.11	-0.09	0.74	0.71	0.41	-0.2
Retained Earnings	0.88	0.75	0.82	0.93	0.59	0.65	0.57		0.48	0.89	0.49	0.45	0.65	-0.14	0.82	0.84	0.79	-0.31	0.83	0.84	0.26	0.5	0.81	0.48	0.9	0.01
Cash	0.73	0.2	0.27	0.42	0.79	0.33	-0.21	0.48		0.69	0.08	0.8	0.31	0.54	0.38	0.75	0.27	0.44	0.35	0.8	0.39	0.81	0.11	0.07	0.6	-0.08
Non Current Assets Total	1.0	0.59	0.68	0.81	0.84	0.53	0.33	0.89	0.69		0.25	0.68	0.57	0.26	0.76	0.92	0.63	0.11	0.72	0.96	0.29	0.79	0.54	0.28	0.95	0.13
Non Currrent Assets Other	0.23	0.69	0.55	0.64	-0.16	0.71	0.66	0.49	0.08	0.25		-0.35	0.61	-0.63	0.53	0.4	0.67	-0.71	0.61	0.17	0.33	-0.08	0.79	0.72	0.31	-0.75
Cash And Short Term Investments	0.74	0.11	0.26	0.28	0.9	0.12	-0.23	0.45	0.8	0.68	-0.35		0.18	0.74	0.34	0.63	0.17	0.61	0.27	0.83	0.18	0.79	-0.09	-0.16	0.62	0.52
Net Receivables	0.57	0.88	0.89	0.57	0.4	0.97	0.74	0.65	0.31	0.57	0.61	0.18		-0.03	0.87	0.57	0.87	-0.28	0.88	0.53	0.06	0.44	0.57	0.85	0.57	-0.28
Common Stock Shares Outstanding	0.3	-0.27	-0.14	-0.25	0.67	-0.14	-0.51	-0.14	0.54	0.26	-0.63	0.74	-0.03		-0.05	0.23	-0.24	0.92	-0.12	0.38	0.07	0.67	-0.61	-0.38	0.19	0.47
Non Current Liabilities Total	0.74	0.95	0.96	0.77	0.47	0.84	0.8	0.82	0.38	0.76	0.53	0.34	0.87	-0.05		0.71	0.9	-0.34	0.99	0.68	0.27	0.47	0.71	0.63	0.79	-0.1
Inventory	0.93	0.58	0.66	0.86	0.72	0.57	0.28	0.84	0.75	0.92	0.4	0.63	0.57	0.23	0.71		0.6	0.03	0.72	0.92	0.52	0.72	0.57	0.25	0.94	-0.05
Other Current Assets	0.62	0.95	0.92	0.76	0.35	0.9	0.84	0.79	0.27	0.63	0.67	0.17	0.87	-0.24	0.9	0.6		-0.47	0.93	0.57	0.28	0.33	0.77	0.79	0.62	-0.21
Other Stockholder Equity	0.15	-0.55	-0.44	-0.43	0.57	-0.36	-0.73	-0.31	0.44	0.11	-0.71	0.61	-0.28	0.92	-0.34	0.03	-0.47		-0.42	0.23	-0.14	0.57	-0.74	-0.48	-0.03	0.46
Total Liab	0.7	0.97	0.98	0.82	0.4	0.87	0.83	0.83	0.35	0.72	0.61	0.27	0.88	-0.12	0.99	0.72	0.93	-0.42		0.64	0.35	0.4	0.76	0.66	0.77	-0.17
Total Current Assets	0.98	0.5	0.61	0.73	0.9	0.5	0.18	0.84	0.8	0.96	0.17	0.83	0.53	0.38	0.68	0.92	0.57	0.23	0.64		0.3	0.82	0.42	0.22	0.91	0.21
Short Term Debt	0.3	0.27	0.22	0.53	0.07	0.16	0.11	0.26	0.39	0.29	0.33	0.18	0.06	0.07	0.27	0.52	0.28	-0.14	0.35	0.3		0.11	0.28	-0.16	0.4	-0.27
Intangible Assets	0.8	0.24	0.37	0.37	0.93	0.39	-0.09	0.5	0.81	0.79	-0.08	0.79	0.44	0.67	0.47	0.72	0.33	0.57	0.4	0.82	0.11		0.08	0.16	0.65	0.15
Accounts Payable	0.5	0.77	0.73	0.86	0.06	0.63	0.74	0.81	0.11	0.54	0.79	-0.09	0.57	-0.61	0.71	0.57	0.77	-0.74	0.76	0.42	0.28	0.08		0.59	0.59	-0.36
Property Plant And Equipment Gross	0.27	0.75	0.69	0.4	0.1	0.89	0.71	0.48	0.07	0.28	0.72	-0.16	0.85	-0.38	0.63	0.25	0.79	-0.48	0.66	0.22	-0.16	0.16	0.59		0.22	-0.48
Common Stock Total Equity	0.95	0.64	0.74	0.87	0.72	0.53	0.41	0.9	0.6	0.95	0.31	0.62	0.57	0.19	0.79	0.94	0.62	-0.03	0.77	0.91	0.4	0.65	0.59	0.22		0.14
Short Term Investments	0.16	-0.24	-0.09	-0.17	0.37	-0.4	-0.2	0.01	-0.08	0.13	-0.75	0.52	-0.28	0.47	-0.1	-0.05	-0.21	0.46	-0.17	0.21	-0.27	0.15	-0.36	-0.48	0.14

Click cells to compare fundamentals

Merck Account Relationship Matchups

Merck fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	84.4B	91.6B	105.7B	109.2B	106.7B	60.3B
Short Long Term Debt Total	26.3B	31.8B	33.1B	30.7B	36.3B	38.1B
Other Current Liab	14.9B	14.7B	15.6B	16.0B	17.5B	18.3B
Total Current Liabilities	22.2B	27.3B	23.9B	24.2B	25.7B	13.3B
Total Stockholder Equity	25.9B	25.3B	38.2B	46.0B	37.6B	25.5B
Property Plant And Equipment Net	15.1B	18.0B	19.3B	21.4B	24.5B	25.7B
Net Debt	16.7B	23.7B	25.0B	18.0B	29.4B	30.8B
Retained Earnings	46.6B	47.4B	53.7B	61.1B	53.9B	32.6B
Cash	9.7B	8.1B	8.1B	12.7B	6.9B	5.6B
Non Current Assets Total	56.9B	63.8B	75.4B	73.4B	74.5B	41.1B
Non Currrent Assets Other	5.3B	9.2B	8.1B	7.7B	10.6B	6.1B
Cash And Short Term Investments	10.5B	8.1B	8.1B	13.2B	7.1B	7.3B
Net Receivables	6.8B	7.2B	9.2B	9.5B	11.7B	12.3B
Common Stock Shares Outstanding	2.6B	2.5B	2.5B	2.5B	2.5B	2.7B
Liabilities And Stockholders Equity	84.4B	91.6B	105.7B	109.2B	106.7B	60.3B
Non Current Liabilities Total	36.2B	38.9B	43.6B	38.9B	43.3B	45.5B
Inventory	6.0B	6.3B	6.0B	5.9B	6.4B	3.7B
Other Current Assets	4.3B	6.9B	7.0B	7.2B	7.0B	7.4B
Other Stockholder Equity	(16.3B)	(17.2B)	(12.9B)	(12.1B)	(12.9B)	(12.3B)
Total Liab	58.4B	66.2B	67.4B	63.1B	69.0B	72.5B
Total Current Assets	27.5B	27.8B	30.3B	35.7B	32.2B	19.2B
Short Term Debt	3.6B	6.7B	2.4B	1.9B	1.7B	2.3B
Intangible Assets	14.2B	14.6B	22.9B	20.3B	18.0B	14.3B
Accounts Payable	3.7B	4.3B	4.6B	4.3B	3.9B	2.8B
Property Plant And Equipment Gross	15.1B	18.0B	37.5B	39.4B	41.3B	43.4B
Accumulated Other Comprehensive Income	(6.2B)	(6.6B)	(4.4B)	(4.8B)	(5.2B)	(4.9B)
Short Term Investments	774M	1M	0.0	498M	252M	239.4M
Other Liab	12.7B	12.1B	11.7B	9.1B	10.5B	10.2B
Other Assets	5.3B	7.8B	9.4B	7.4B	8.5B	5.5B
Long Term Debt	22.7B	25.4B	30.7B	28.7B	33.7B	17.2B
Good Will	19.4B	20.2B	21.3B	21.2B	21.2B	12.3B
Treasury Stock	(56.0B)	(56.8B)	(57.1B)	(56.5B)	(57.5B)	(54.6B)
Property Plant Equipment	15.1B	18.0B	19.3B	21.4B	24.6B	16.2B
Net Tangible Assets	(7.7B)	(9.5B)	3.5B	4.5B	4.1B	4.5B
Noncontrolling Interest In Consolidated Entity	94M	87M	73M	67M	54M	51.3M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Merck Company is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Merck Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Merck Company Stock. Highlighted below are key reports to facilitate an investment decision about Merck Company Stock:

How To Invest In Merck

Details

Is Merck Stock a good investment?

Details

What is Merck's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Merck Company. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Merck. If investors know Merck will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Merck listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.33)

Dividend Share

3.04

Earnings Share

4.78

Revenue Per Share

24.931

Quarterly Revenue Growth

0.044

The market value of Merck Company is measured differently than its book value, which is the value of Merck that is recorded on the company's balance sheet. Investors also form their own opinion of Merck's value that differs from its market value or its book value, called intrinsic value, which is Merck's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Merck's market value can be influenced by many factors that don't directly affect Merck's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Merck's value and its price as these two are different measures arrived at by different means. Investors typically determine if Merck is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Merck's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Merck Begin Period Cash Flow vs Cash Per Share Analysis

Begin Period Cash Flow vs Cash Per Share

Begin Period Cash Flow vs Cash Per Share Correlation Analysis

Correlation Coefficient

Begin Period Cash Flow

Cash Per Share

Merck fundamental ratios Correlations

Merck Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Merck fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Current Assets Total	+ 1.0	Total Assets
Total Liab	+ 0.99	Non Current Liabilities Total
Total Current Assets	+ 0.98	Total Assets
Total Liab	+ 0.98	Other Current Liab
Total Liab	+ 0.97	Short Long Term Debt Total
Net Receivables	+ 0.97	Property Plant And Equipment Net

Short Term Investments	- 0.75	Non Currrent Assets Other
Accounts Payable	- 0.74	Other Stockholder Equity
Other Stockholder Equity	- 0.73	Net Debt
Other Stockholder Equity	- 0.71	Non Currrent Assets Other
Common Stock Shares Outstanding	- 0.63	Non Currrent Assets Other
Accounts Payable	- 0.61	Common Stock Shares Outstanding